A detailed history of Baker Bros. Advisors LP transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 3,882,125 shares of NRIX stock, worth $77 Million. This represents 0.93% of its overall portfolio holdings.

Number of Shares
3,882,125
Previous 3,882,125 -0.0%
Holding current value
$77 Million
Previous $81 Million 7.57%
% of portfolio
0.93%
Previous 1.08%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

BUY
$7.88 - $14.82 $11.3 Million - $21.2 Million
1,428,043 Added 58.19%
3,882,125 $49.2 Million
Q1 2021

May 17, 2021

BUY
$26.98 - $50.17 $17.9 Million - $33.4 Million
665,161 Added 37.18%
2,454,082 $76.3 Million
Q3 2020

Nov 16, 2020

BUY
$16.05 - $34.91 $28.7 Million - $62.5 Million
1,788,921 New
1,788,921 $62.5 Million

Others Institutions Holding NRIX

About Nurix Therapeutics, Inc.


  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $935M
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.